Structural characterization and anticancer properties of a novel mushroom-derived rhamnogalactan in a triple-negative breast cancer model

Mushroom-derived polysaccharides are known for their diverse biological activities, including immunomodulatory and anticancer properties. Breast cancer, the leading cause of cancer-related death among women worldwide, lacks targeted molecular therapies, underscoring the need for novel therapeutic ag...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Carbohydrate polymers Ročník 364; s. 123735
Hlavní autori: de Lara, Eliane Leal, Zavadinack, Matheus, da Silva Milhorini, Shayane, Wurzer, Karin Maciel, Klassen, Giseli, Cordeiro, Lucimara M.C., Iacomini, Marcello
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Elsevier Ltd 15.09.2025
Predmet:
ISSN:0144-8617, 1879-1344, 1879-1344
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Mushroom-derived polysaccharides are known for their diverse biological activities, including immunomodulatory and anticancer properties. Breast cancer, the leading cause of cancer-related death among women worldwide, lacks targeted molecular therapies, underscoring the need for novel therapeutic agents. In this study, we extracted, purified, and characterized a novel heteropolysaccharide (HTP) - a rhamnogalactan - composed of galactose (72.6 %) and rhamnose (27.4 %) from the edible mushroom Lactarius quieticolor. Structural analysis revealed that HTP consists of a (1 → 6)-linked α-d-galactopyranose backbone, heavily substituted at O-2 by non-reducing rhamnose units, with a weight-average molar mass of 2.41 × 104 g.mol−1. In vitro assays using a triple-negative breast cancer (TNBC) cell model - the most aggressive subtype - showed a significant reduction in cell viability (50 % at 1200 μg·mL−1). Furthermore, an additive effect was observed when co-administered with the chemotherapy drug paclitaxel, reducing the cell viability to 42 %. These findings suggest potential therapeutic applications of the purified mushroom rhamnogalactan reported in this study against TNBC. [Display omitted]
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0144-8617
1879-1344
1879-1344
DOI:10.1016/j.carbpol.2025.123735